J Crohns Colitis. 2025 Sep 19:jjaf172. doi: 10.1093/ecco-jcc/jjaf172. Online ahead of print.
ABSTRACT
BACKGROUND: External validation of predictors of anti-tumor necrosis factor (TNF) outcomes remains limited, particularly in children. We conducted a systematic review (SR) of the literature to identify predictors of therapeutic success and validated them in a prospective pediatric cohort.
METHODS: We searched PubMed and Embase for studies reporting clinical and laboratory predictors of anti-TNF outcomes in Crohn’s disease (CD). Identified predictors were evaluated in a prospective cohort of 186 children with CD initiating anti-TNF. Univariable logistic regression assessed individual predictors, and previously published multivariable models were validated using the area under the curve (AUC).
RESULTS: Of the 4,840 studies screened, 42 were included; 7 (17%) focused on children and only four were rated as low risk of bias. We identified 24 individual predictors and five multi-item models. Of these, prior corticosteroid use (odds ratio [OR], 2.84, 95% CI, 1.12-7.15) and immunomodulator combination therapy (OR 6.36, 95% CI, 2.39-17.10) were associated with increased risk of primary non-response. Disease activity at 4 months, reflected by C-reactive protein and disease activity indices, predicted remission at 12 months. Loss of response was associated with elevated inflammatory markers at 4 months and with partial clinical response. The five multivariable models demonstrated varying performance in children (AUC 0.54-0.76).
CONCLUSION: Only a few of the variables suggested to predict response to anti-TNF showed acceptable performance in pediatric CD, mainly those that included post-induction indicators. These findings highlight the limited generalizability of existing predictors and the importance of external validation before clinical implementation of prediction rules.
PMID:40973786 | DOI:10.1093/ecco-jcc/jjaf172
